Verastem Inc VSTM LGSOC Program Update Call Transcript
Good evening, and welcome to the Verastem Oncology Investor Conference Call on Tuesday, January 24, 2023. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.
At this time, I would like to introduce Mr. Daniel Calkins, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.
Thank you. Hello. Welcome, everyone, and thank you for joining us today to discuss the interim data from Part A of the ongoing RAMP 201 international registration-directed Phase II study evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer, which will be -- which we will be referring to today as LGSOC. The company will also provide our regulatory update following a productive meeting with the FDA.
Today's speakers include
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |